gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ZBIOHealthcarePharmaceuticals

Zenas BioPharma, Inc. Common Stock (ZBIO)

$28.46+0.28%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$28.50▼ 9.02% in range
Nov 3, 2025Low $15.20 · High $43.17Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Zenas BioPharma closed at $28.46 on Nov 4, up 0.28%, 34.1% below its 52-week closing high. Volume of 800.7K shares was 1.64× its 20-day average (above normal).

Split-adjusted performance: +5.6% over one month, +36.6% over six months, -9.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $1M, with a net margin of -11145.6%.

Short interest was 12.5M shares at the Oct 15 settlement, up 5.0% from the prior report (40.2% of float, 18.8 days to cover).

Market cap$1.85B65.2M shares
Revenue · quarter$1.0M—
Diluted EPS$-1.77—
P/E · TTM—P/S 1,854.9×
Net margin-11,145.6%Gross 100.0%
Dividend yieldNone$0.002 last paid
52-week range15.20 – 43.17−34.1% from high
Volume800.7K1.64× 20-day avg
Volatility · 60d55.8%Annualised
Short % of float40.2%18.8 days to cover
Net cash$346.1MCash $643.1M
Next earnings—Not scheduled
Split-adjusted performance
1W −1.1%1M +5.6%3M −11.5%6M +36.6%YTD −21.6%1Y −9.2%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum89
Revenue growth—
Net margin5
Value (low P/E)—
Size80

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short12.5M+5.0% vs prior
Days to cover18.8Settled Oct 15
% of float40.2%
Short vol. 10d54.2%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ZBIOZenas BioPharma$28.46+0.28%+36.6%—−11145.6%—$1.85B
SLSSELLAS Life Sciences Group$9.14+3.04%+77.5%———$1.85BCompare
AGIOAgios Pharmaceuticals$31.38+0.58%+16.3%+259.3%−225.1%—$1.87BCompare
GENBGenerate Biomedicines$14.16+2.24%——−1065.2%—$1.82BCompare
BRVEBraveheart Bio$20.11−6.01%————$1.81BCompare
PGENPrecigen$5.06−3.71%+14.9%+6322.7%36.5%—$1.81BCompare
XERSXeris Biopharma Holdings$10.46+1.06%+64.2%+28.7%−33.8%—$1.91BCompare
STOKStoke Therapeutics$27.45+1.70%−17.5%+5.9%−654.3%—$1.77BCompare
NRIXNurix Therapeutics$15.95−38.23%−5.5%+8426.3%81.7%5.9$1.74BCompare

News about Zenas BioPharma

All news →
Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should KnowZacks Investment Research · Oct 23, 2026▲ PositiveZenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related DiseaseGlobeNewswire Inc. · Oct 12, 2026▲ PositiveZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Sep 18, 2026NeutralZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of MedicineGlobeNewswire Inc. · Jun 2, 2026▲ PositiveZenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire Inc. · May 13, 2026▲ Positive

Quick answers

What does Zenas BioPharma do?
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
What is ZBIO's market cap?
$1.85B, based on the Nov 4 close of $28.46.
Does Zenas BioPharma pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ZBIO is sold short?
12.5M shares, 40.2% of float, as of Oct 15, 2026.
What sector is ZBIO in?
Healthcare, in the Pharmaceuticals industry.

About Zenas BioPharma

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

HQ: Waltham, MA167 employeesListed Sep 13, 2024zenasbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology